痛风治疗药物市场规模、份额、趋势分析报告：按类别、按疾病、按分销渠道、按地区、细分趋势：2023-2030

痛风治疗市场增长和趋势

根据Grand View Research, Inc.的最新报告，预计到2030年，全球痛风药物市场将达到41.3亿美元，2023年至2030年復合年增长率为6.25%。

市场发展是由日益增加的全球疾病负担、政府和私人组织为提高公众意识所做的努力以及该领域新疗法的最新发展推动的。此外，临床管线药物数量的增加也带来了利润丰厚的市场增长机会。

在全球范围内，痛风的患病率正在增加，这是推动市场增长的关键因素。例如，Elsevier的一篇论文报告称，2021年，澳大利亚痛风患病率将在1.5%至2.9%之间。同样，2021 年，加拿大和英国报告的疾病病例分别增加了约 4% 和 2.33%。老年人口数量的增加、酒精和果糖摄入量等不良饮食习惯、久坐生活方式的增加以及肾功能不全、心血管疾病和糖尿病等合併症进一步支持了这种高患病率。我在这里。

强大的临床试验管道和预期的新疗法推出预计将在预测期内推动市场增长。目前，Jiangsu HengRui Medicine Co, Ltd.的SHR4640等候选新药正处于治疗痛风的3期临床试验中。同样，2023 年 3 月，Selecta Biosciences, Inc. 宣布了 SEL-212 3 期 DISSOLVE I 和 II 安慰剂对照随机临床试验的积极结果。SEL-212适用于慢性顽固性痛风。

主要参与者正在做出联合研究、併购、合同和金融投资等战略努力，以推动市场的增长。例如，2021 年 6 月，Horizon Therapeutics plc 与 Arrowhead Pharmaceuticals 合作开发一种潜在的 RNAi 疗法，用于治疗不受控制的痛风。2022年7月，该公司获得 FDA 对 Krystexxa 的扩大批准，用于治疗未受控制的痛风患者。该药物与免疫疗法和化疗药物甲氨蝶呤一起使用。

此外，2023 年 3 月，Horizon 发起了全国肾臟月活动“Weed it G'out”。该活动利用鲜花和杂草来关联尿酸对肾臟的影响。该活动旨在提高人们对痛风的认识，鼓励人们认真对待痛风并寻求专业帮助。

痛风治疗市场报告亮点

• 由于高处方率、低成本和强大的市场占有率，非甾体抗炎药 (NSAID) 细分市场在 2022 年占据最大的市场份额。
• 按疾病划分，由于患者数量高于慢性病，因此到 2022 年，急性病细分市场将占总市场份额的 65.77%
• 2022年，零售药店占据该领域最高的细分市场份额。然而，在线药店将在预测期内增长最快
• 由于痛风患病率上升、个人对疾病治疗的认识较高以及该地区获得良好的医疗保健等因素，北美在 2022 年将主导全球市场。
• 该领域的领先公司包括 GlaxoSmithKline plc、Takeda Pharmaceutical Company Ltd.、Regeneron Pharmaceuticals Inc、Novartis AG、AstraZeneca plc、Merck & Co. Inc.、Teijin Ltd.、Horizon Pharma plc 和 Zydus Group。

目录

第一章 调查方法和范围

• 市场细分
  • 估计/预测时间表
• 市场定义
• 调查方法
• 信息采购
  • 购买的数据库
  • 次要信息
  • 初步调查
  • 初步调查详情
• 信息或数据分析
  • 数据分析模型
• 市场形成和验证
• 型号详情
  • 产品流向分析
• 区域市场：计算复合年增长率
• 调查假设
• 二级信息列表
• 缩略语表
• 目的

第二章执行摘要

• 市场快照
• 药物类别和病情细分的快照
• 分销渠道细分快照
• 竞争格局的快照

3.全球痛风治疗市场变量、趋势和范围

• 痛风治疗市场前景展望
  • 母公司市场展望
• 绘製采用和增长前景图
• 监管框架
• 市场驱动力分析
  • 痛风患病率上升
  • 强大的研发管线带来先进的新疗法
  • 提高公众意识
• 市场约束因素分析
  • 发展中国家和欠发达国家的疾病诊断延迟
• 波特五力分析
• 管道分析

4 痛风药物市场：细分分析，按药物类别，2018-2030（百万美元）

• 全球痛风治疗市场：药物类别变化分析
• 非甾体抗炎药
  • 2018-2030 年非甾体抗炎药市场估计和预测（百万美元）
• 皮质类固醇
  • 2018-2030 年皮质类固醇市场估计和预测（百万美元）
• 秋水仙碱
  • 2018-2030 年秋水仙碱市场估计和预测（百万美元）
• 降尿酸剂
  • 降尿酸剂市场估计和预测，2018-2030 年（百万美元）
• 其他
  • 2018-2030 年其他市场估计和预测（百万美元）

第五章 痛风药物：按疾病分类分析，2018-2030（百万美元）

• 全球痛风治疗市场：疾病变异分析
• 急性痛风
  • 2018-2030 年急性痛风市场估计和预测（百万美元）
• 慢性痛风
  • 2018-2030 年慢性痛风市场估计和预测（百万美元）

6 痛风药物市场：2018-2030 年按分销渠道细分分析（百万美元）

• 全球痛风治疗市场：分销渠道变化分析
• 医院药房
  • 2018-2030 年医院药房市场估计和预测（百万美元）
• 零售药店
  • 2018-2030 年零售药房市场估计和预测（百万美元）
• 网上药店
  • 2018-2030 年在线药房市场估计和预测（百万美元）

7. 痛风治疗市场：2018-2030 年按地区细分分析（百万美元）

• 痛风治疗市场：区域差异分析
  • 定义和范围
• 北美
  • 北美，SWOT 分析
  • 美国
  • 加拿大
• 欧洲
  • 欧洲，SWOT分析
  • 英国
  • 德国
  • 法国
  • 意大利
  • 西班牙
  • 瑞典
  • 丹麦
  • 挪威
• 亚太地区
  • 亚太地区，SWOT分析
  • 印度
  • 中国
  • 日本
  • 澳大利亚
  • 韩国
  • 泰国
• 拉丁美洲
  • 拉丁美洲，SWOT分析
  • 墨西哥
  • 巴西
  • 阿根廷
• MEA
  • 中东和非洲，SWOT 分析
  • 南非
  • 沙特阿拉伯
  • 阿拉伯联合酋长国
  • 科威特

第8章 竞争格局

• 上市公司
  • 公司市场分析
  • 竞争仪錶盘分析
  • 战略框架
• 民营企业
  • 关键初创企业/技术颠覆者/创新者名单
  • 区域网络图
• 公司简介
  • Takeda Pharmaceutical Company Ltd.
  • Novartis Ag
  • Regeneron Pharmaceuticals Inc.
  • Astrazeneca Plc
  • Horizon Therapeutics Plc
  • Merck &Co. Inc
  • Zydus Group
  • Teijin Ltd
  • Glaxosmithkline Plc

Gout Therapeutics Market Growth & Trends

The global gout therapeutics market size is expected to reach USD 4.13 billion by 2030 and expand at a CAGR of 6.25% from 2023 to 2030, according to a new report by Grand View Research, Inc. The growth of the market is attributed to the global rise in disease burden, initiatives undertaken by government and private organizations to spread awareness among people, and the recent development of novel therapies in the space. Furthermore, the growing number of clinical pipeline drugs offers lucrative market growth opportunities.

The world is witnessing an increasing prevalence of gout, which is the key factor driving market growth. For instance, according to an Elsevier article, in 2021, Australia reported prevalence rates between 1.5% to 2.9% for gout. Similarly, in 2021, Canada and UK reported approximately 4% and 2.33% rise in disease cases respectively. High prevalence is further supported by the high geriatric population, improper diets such as consumption of alcohol and fructose, increasing sedentary lifestyle, and comorbidities like renal impairment, cardiovascular diseases, and diabetes.

The robust clinical trial pipeline and the anticipated launch of new therapeutics are expected to boost market growth over the forecast period. Presently, drug candidates like Jiangsu HengRui Medicine Co., Ltd.'s SHR4640 are in phase 3 clinical investigation for the treatment of gout. Similarly, in March 2023, Selecta Biosciences, Inc announced positive results for the Phase 3 DISSOLVE I & II placebo-controlled randomized clinical trials of SEL-212. SEL-212 is indicated for chronic refractory gout.

Key players are undertaking strategic initiatives such as collaborations, mergers and acquisitions, agreements, and financial investments, driving market growth. For instance, in June 2021, Horizon Therapeutics plc collaborated with Arrowhead Pharmaceuticals to develop RNAi therapeutic, a potential treatment for uncontrolled gout. In July 2022, the company received expanded FDA approval for Krystexxa for patients with uncontrolled gout. It is used in combination with immunotherapy and chemotherapy drug, methotrexate.

Additionally, in March 2023, Horizon organized a campaign, "Weed it G'out" for National Kidney Month. The campaign uses flowers and weeds to depict the correlation to the effect of uric acid on kidneys. The campaign aims to create awareness and urge people to take gout seriously and consult a specialist.

Gout Therapeutics Market Report Highlights

• NSAIDs segment accounted for the largest share of the market in 2022 due to the high prescription rate, low cost, and strong presence in the market.
• Based on disease condition, the acute condition segment held 65.77% of the total market share in 2022, owing to a high patient pool compared to the chronic condition
• In 2022, retail pharmacy held the highest segment share in the space. However, online pharmacy is expected to be the fastest-growing segment over the forecast period
• North America dominated the global market in 2022 owing to factors such as increased gout cases, high awareness among individuals for disease treatment, and better healthcare access in the region
• Some key players in the space include GlaxoSmithKline plc; Takeda Pharmaceutical Company Ltd.; Regeneron Pharmaceuticals Inc; Novartis AG; AstraZeneca plc; Merck & Co. Inc.; Teijin Ltd.; and Horizon Pharma plc; Zydus Group and others

Table of Contents

Chapter 1 Methodology And Scope

• 1.1 Market Segmentation
  • 1.1.1 Estimates And Forecast Timeline
• 1.2 Market Definitions
• 1.3 Research Methodology
• 1.4 Information Procurement
  • 1.4.1 Purchased Database
  • 1.4.2 Secondary Sources
  • 1.4.3 Primary Research
  • 1.4.4 Details Of Primary Research
• 1.5 Information Or Data Analysis
  • 1.5.1 Data Analysis Models
• 1.6 Market Formulation & Validation
• 1.7 Model Details
  • 1.7.1 Commodity Flow Analysis
    • 1.7.1.1 Approach 1: Commodity Flow Approach
    • 1.7.1.2 Approach 2: Country-Wise Market Estimation Using The Bottom-Up Approach
• 1.8 Regional Market: Cagr Calculation
• 1.9 Research Assumptions
• 1.10 List Of Secondary Sources
• 1.11 List Of Abbreviations
• 1.12 Objectives
  • 1.12.1 Objective 1
  • 1.12.2 Objective 2

Chapter 2 Executive Summary

• 2.1 Market Snapshot
• 2.2 Drug Class And Disease Condition Segment Snapshot
• 2.3 Distribution Chanel Segment Snapshot
• 2.4 Competitive Landscape Snapshot

Chapter 3 Global Gout Therapeutics Market Variables, Trends, & Scope

• 3.1 Gout Therapeutics Market Lineage Outlook
  • 3.1.1 Parent Market Outlook
• 3.2 Penetration And Growth Prospect Mapping
• 3.3 Regulatory Framework
• 3.4 Market Driver Analysis
  • 3.4.1 Rising Prevalence Of Gout
  • 3.4.2 Advanced And New Therapies With Strong R&D Pipeline
  • 3.4.3 Rising Awareness Among People
• 3.5 Market Restraint Analysis
  • 3.5.1 Delayed Disease Diagnosis In Developing And Underdeveloped Countries
• 3.6 Porter's Five Forces Analysis
• 3.7 Pipeline Analysis

Chapter 4 Gout Therapeutics Market - Segment Analysis, By Drug Class, 2018 - 2030 (USD Million)

• 4.1 Global Gout Therapeutics Market: Drug Class Movement Analysis
• 4.2. Nsaids
  • 4.2.1. Nsaids Market Estimates And Forecasts, 2018 - 2030 (USD Million)
• 4.3. Corticosteroids
  • 4.3.1 Corticosteroids Market Estimates And Forecasts, 2018 - 2030 (USD Million)
• 4.4. Colchicine
  • 4.4.1 Colchicine Market Estimates And Forecasts, 2018 - 2030 (USD Million)
• 4.5. Urate-Lowering Agents
  • 4.5.1 Urate-Lowering Agents Market Estimates And Forecasts, 2018 - 2030 (USD Million)
• 4.6. Others
  • 4.6.1 Others Market Estimates And Forecasts, 2018 - 2030 (USD Million)

Chapter 5 Gout Therapeutics - Segment Analysis, By Disease Condition, 2018 - 2030 (USD Million)

• 5.1. Global Gout Therapeutics Market: Disease Condition Movement Analysis
• 5.2. Acute Gout
  • 5.2.1. Acute Gout Market Estimates And Forecasts, 2018 - 2030 (USD Million)
• 5.3. Chronic Gout
  • 5.3.1. Chronic Gout Market Estimates And Forecasts, 2018 - 2030 (USD Million)

Chapter 6 Gout Therapeutics Market- Segment Analysis, By Distribution Channel, 2018 - 2030 (USD Million)

• 6.1. Global Gout Therapeutics Market: Distribution Channel Movement Analysis
• 6.2. Hospital Pharmacy
  • 6.2.1. Hospital Pharmacy Market Estimates And Forecasts, 2018 - 2030 (USD Million)
• 6.3. Retail Pharmacy
  • 6.3.1. Retail Pharmacy Market Estimates And Forecasts, 2018 - 2030 (USD Million)
• 6.4. Online Pharmacy
  • 6.4.1. Online Pharmacy Market Estimates And Forecasts, 2018 - 2030 (USD Million)

Chapter 7 Gout Therapeutics Market: - Segment Analysis, By Region, 2018 - 2030 (USD Million)

• 7.1 Gout Therapeutics Market: Regional Movement Analysis
  • 7.1.1 Definition & Scope
• 7.2 North America
  • 7.2.1 North America, Swot Analysis
  • 7.2.2 U.S.
    • 7.2.2.1 U.S. Market Estimates And Forecast, 2018 - 2030 (USD Million)
    • 7.2.2.2 Key Country Dynamics
    • 7.2.2.3 Target Disease Prevalence
    • 7.2.2.4 Competitive Scenario
    • 7.2.2.5 Regulatory Framework
    • 7.2.2.6 Reimbursement Scenario
  • 7.2.3 Canada
    • 7.2.3.1 Canada Market Estimates And Forecast, 2018 - 2030 (USD Million)
    • 7.2.3.2 Key Country Dynamics
    • 7.2.3.3 Target Disease Prevalence
    • 7.2.3.4 Competitive Scenario
    • 7.2.3.5 Regulatory Framework
    • 7.2.3.6 Reimbursement Scenario
• 7.3 Europe
  • 7.3.1 Europe, Swot Analysis
  • 7.3.2 Uk
    • 7.3.2.1 Uk Market Estimates And Forecast, 2018 - 2030 (USD Million)
    • 7.3.2.2 Key Country Dynamics
    • 7.3.2.3 Target Disease Prevalence
    • 7.3.2.4 Competitive Scenario
    • 7.3.2.5 Regulatory Framework
    • 7.3.2.6 Reimbursement Scenario
  • 7.3.3 Germany
    • 7.3.3.1 Germany Market Estimates And Forecast, 2018 - 2030 (USD Million)
    • 7.3.3.2 Key Country Dynamics
    • 7.3.3.3 Target Disease Prevalence
    • 7.3.3.4 Competitive Scenario
    • 7.3.3.5 Regulatory Framework
    • 7.3.3.6 Reimbursement Scenario
  • 7.3.4 France
    • 7.3.4.1 France Market Estimates And Forecast, 2018 - 2030 (USD Million)
    • 7.3.4.2 Key Country Dynamics
    • 7.3.4.3 Target Disease Prevalence
    • 7.3.4.4 Competitive Scenario
    • 7.3.4.5 Regulatory Framework
    • 7.3.4.6 Reimbursement Scenario
  • 7.3.5 Italy
    • 7.3.5.1 Italy Market Estimates And Forecast, 2018 - 2030 (USD Million)
    • 7.3.5.2 Key Country Dynamics
    • 7.3.5.3 Target Disease Prevalence
    • 7.3.5.4 Competitive Scenario
    • 7.3.5.5 Regulatory Framework
    • 7.3.5.6 Reimbursement Scenario
  • 7.3.6 Spain
    • 7.3.6.1 Spain Market Estimates And Forecast, 2018 - 2030 (USD Million)
    • 7.3.6.2 Key Country Dynamics
    • 7.3.6.3 Target Disease Prevalence
    • 7.3.6.4 Competitive Scenario
    • 7.3.6.5 Regulatory Framework
    • 7.3.6.6 Reimbursement Scenario
  • 7.3.7 Sweden
    • 7.3.7.1 Sweden Market Estimates And Forecast, 2018 - 2030 (USD Million)
    • 7.3.7.2 Key Country Dynamics
    • 7.3.7.3 Target Disease Prevalence
    • 7.3.7.4 Competitive Scenario
    • 7.3.7.5 Regulatory Framework
    • 7.3.7.6 Reimbursement Scenario
  • 7.3.8 Denmark
    • 7.3.8.1 Denmark Market Estimates And Forecast, 2018 - 2030 (USD Million)
    • 7.3.8.2 Key Country Dynamics
    • 7.3.8.3 Target Disease Prevalence
    • 7.3.8.4 Competitive Scenario
    • 7.3.8.5 Regulatory Framework
    • 7.3.8.6 Reimbursement Scenario
  • 7.3.9 Norway
    • 7.3.9.1 Norway Market Estimates And Forecast, 2018 - 2030 (USD Million)
    • 7.3.9.2 Key Country Dynamics
    • 7.3.9.3 Target Disease Prevalence
    • 7.3.9.4 Competitive Scenario
    • 7.3.9.5 Regulatory Framework
    • 7.3.9.6 Reimbursement Scenario
• 7.4 Asia Pacific
  • 7.4.1 Asia Pacific, Swot Analysis
  • 7.4.2 India
    • 7.4.2.1 India Market Estimates And Forecast, 2018 - 2030 (USD Million)
    • 7.4.2.2 Key Country Dynamics
    • 7.4.2.3 Target Disease Prevalence
    • 7.4.2.4 Competitive Scenario
    • 7.4.2.5 Regulatory Framework
    • 7.4.2.6 Reimbursement Scenario
  • 7.4.3 China
    • 7.4.3.1 China Market Estimates And Forecast, 2018 - 2030 (USD Million)
    • 7.4.3.2 Key Country Dynamics
    • 7.4.3.3 Target Disease Prevalence
    • 7.4.3.4 Competitive Scenario
    • 7.4.3.5 Regulatory Framework
    • 7.4.3.6 Reimbursement Scenario
  • 7.4.4 Japan
    • 7.4.4.1 Japan Market Estimates And Forecast, 2018 - 2030 (USD Million)
    • 7.4.4.2 Key Country Dynamics
    • 7.4.4.3 Target Disease Prevalence
    • 7.4.4.4 Competitive Scenario
    • 7.4.4.5 Regulatory Framework
    • 7.4.4.6 Reimbursement Scenario
  • 7.4.5 Australia
    • 7.4.5.1 Australia Market Estimates And Forecast, 2018 - 2030 (USD Million)
    • 7.4.5.2 Key Country Dynamics
    • 7.4.5.3 Target Disease Prevalence
    • 7.4.5.4 Competitive Scenario
    • 7.4.5.5 Regulatory Framework
    • 7.4.5.6 Reimbursement Scenario
  • 7.4.6 South Korea
    • 7.4.6.1 South Korea Market Estimates And Forecast, 2018 - 2030 (USD Million)
    • 7.4.6.2 Key Country Dynamics
    • 7.4.6.3 Target Disease Prevalence
    • 7.4.6.4 Competitive Scenario
    • 7.4.6.5 Regulatory Framework
    • 7.4.6.6 Reimbursement Scenario
  • 7.4.7 Thailand
    • 7.4.7.1 Thailand Market Estimates And Forecast, 2018 - 2030 (USD Million)
    • 7.4.7.2 Key Country Dynamics
    • 7.4.7.3 Target Disease Prevalence
    • 7.4.7.4 Competitive Scenario
    • 7.4.7.5 Regulatory Framework
    • 7.4.7.6 Reimbursement Scenario
• 7.5 Latin America
  • 7.5.1 Latin America, Swot Analysis
  • 7.5.2 Mexico
    • 7.5.2.1 Mexico Market Estimates And Forecast, 2018 - 2030 (USD Million)
    • 7.5.2.2 Key Country Dynamics
    • 7.5.2.3 Target Disease Prevalence
    • 7.5.2.4 Competitive Scenario
    • 7.5.2.5 Regulatory Framework
    • 7.5.2.6 Reimbursement Scenario
  • 7.5.3 Brazil
    • 7.5.3.1 Brazil Market Estimates And Forecast, 2018 - 2030 (USD Million)
    • 7.5.3.2 Key Country Dynamics
    • 7.5.3.3 Target Disease Prevalence
    • 7.5.3.4 Competitive Scenario
    • 7.5.3.5 Regulatory Framework
    • 7.5.3.6 Reimbursement Scenario
  • 7.5.4 Argentina
    • 7.5.4.1 Argentina Market Estimates And Forecast, 2018 - 2030 (USD Million)
    • 7.5.4.2 Key Country Dynamics
    • 7.5.4.3 Target Disease Prevalence
    • 7.5.4.4 Competitive Scenario
    • 7.5.4.5 Regulatory Framework
    • 7.5.4.6 Reimbursement Scenario
• 7.6 MEA
  • 7.6.1 Middle East & Africa, Swot Analysis
  • 7.6.2 South Africa
    • 7.6.2.1 South Africa Market Estimates And Forecast, 2018 - 2030 (USD Million)
    • 7.6.2.2 Key Country Dynamics
    • 7.6.2.3 Target Disease Prevalence
    • 7.6.2.4 Competitive Scenario
    • 7.6.2.5 Regulatory Framework
    • 7.6.2.6 Reimbursement Scenario
  • 7.6.3 Saudi Arabia
    • 7.6.3.1 Saudi Arabia Market Estimates And Forecast, 2018 - 2030 (USD Million)
    • 7.6.3.2 Key Country Dynamics
    • 7.6.3.3 Target Disease Prevalence
    • 7.6.3.4 Competitive Scenario
    • 7.6.3.5 Regulatory Framework
    • 7.6.3.6 Reimbursement Scenario
  • 7.6.4 UAE
    • 7.6.4.1 UAE Market Estimates And Forecast, 2018 - 2030 (USD Million)
    • 7.6.4.2 Key Country Dynamics
    • 7.6.4.3 Target Disease Prevalence
    • 7.6.4.4 Competitive Scenario
    • 7.6.4.5 Regulatory Framework
    • 7.6.4.6 Reimbursement Scenario
  • 7.6.5 Kuwait
    • 7.6.5.1 Kuwait Market Estimates And Forecast, 2018 - 2030 (USD Million)
    • 7.6.5.2 Key Country Dynamics
    • 7.6.5.3 Target Disease Prevalence
    • 7.6.5.4 Competitive Scenario
    • 7.6.5.5 Regulatory Framework
    • 7.6.5.6 Reimbursement Scenario

Chapter 8 Competitive Landscape

• 8.1 Public Companies
  • 8.1.1 Company Market Position Analysis
  • 8.1.2 Competitive Dashboard Analysis
  • 8.1.3 Strategic Framework
• 8.2 Private Companies
  • 8.2.1 List Of Key Emerging Companies/Technology Disruptors/Innovators
  • 8.2.2 Regional Network Map
• 8.3 Company Profiles
  • 8.3.1 Takeda Pharmaceutical Company Ltd.
    • 8.3.1.1 Company Overview
    • 8.3.1.2 Financial Performance
    • 8.3.1.3 Product Benchmarking
    • 8.3.1.4 Strategic Initiatives
  • 8.3.2 Novartis Ag
    • 8.3.2.1 Company Overview
    • 8.3.2.2 Financial Performance
    • 8.3.2.3 Product Benchmarking
    • 8.3.2.4 Strategic Initiatives
  • 8.3.3 Regeneron Pharmaceuticals Inc.
    • 8.3.3.1 Company Overview
    • 8.3.3.2 Financial Performance
    • 8.3.3.3 Product Benchmarking
    • 8.3.3.4 Strategic Initiatives
  • 8.3.4 Astrazeneca Plc
    • 8.3.4.1 Company Overview
    • 8.3.4.2 Financial Performance
    • 8.3.4.3 Product Benchmarking
    • 8.3.4.4 Strategic Initiatives
  • 8.3.5 Horizon Therapeutics Plc
    • 8.3.5.1 Company Overview
    • 8.3.5.2 Financial Performance
    • 8.3.5.3 Product Benchmarking
    • 8.3.5.4 Strategic Initiatives
  • 8.3.6 Merck & Co. Inc
    • 8.3.6.1 Company Overview
    • 8.3.6.2 Financial Performance
    • 8.3.6.3 Product Benchmarking
    • 8.3.6.4 Strategic Initiatives
  • 8.3.7 Zydus Group
    • 8.3.7.1 Company Overview
    • 8.3.7.2 Financial Performance
    • 8.3.7.3 Product Benchmarking
    • 8.3.7.4 Strategic Initiatives
  • 8.3.8 Teijin Ltd
    • 8.3.8.1 Company Overview
    • 8.3.8.2 Financial Performance
    • 8.3.8.3 Product Benchmarking
    • 8.3.8.4 Strategic Initiatives
  • 8.3.9 Glaxosmithkline Plc
    • 8.3.9.1 Company Overview
    • 8.3.9.2 Financial Performance
    • 8.3.9.3 Product Benchmarking
    • 8.3.9.4 Strategic Initiatives

List of Tables

• Table 1 List of Secondary Sources
• Table 2 List of Abbreviation
• Table 3 List of Parameters
• Table 4 List of Distributors
• Table 5 Global Gout Therapeutics Market, By Region, 2018 - 2030 (USD Million)
• Table 6 Global Gout Therapeutics Market, By Drug Class, 2018 - 2030 (USD Million)
• Table 7 Global Gout Therapeutics Market, By Disease Condition, 2018 - 2030 (USD Million)
• Table 8 Global Gout Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 9 North America Gout Therapeutics Market, By Country, 2018 - 2030 (USD Million)
• Table 10 North America Gout Therapeutics Market, By Drug Class, 2018 - 2030 (USD Million)
• Table 11 North America Gout Therapeutics Market, By Disease Condition, 2018 - 2030 (USD Million)
• Table 12 North America Gout Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 13 U.S. Gout Therapeutics Market, By Drug Class, 2018 - 2030 (USD Million)
• Table 14 U.S. Gout Therapeutics Market, By Disease Condition, 2018 - 2030 (USD Million)
• Table 15 U.S. Gout Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 16 Canada Gout Therapeutics Market, By Drug Class, 2018 - 2030 (USD Million)
• Table 17 Canada Gout Therapeutics Market, By Disease Condition, 2018 - 2030 (USD Million)
• Table 18 Canada Gout Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 19 Europe Gout Therapeutics Market, By Country, 2018 - 2030 (USD Million)
• Table 20 Europe Gout Therapeutics Market, By Drug Class, 2018 - 2030 (USD Million)
• Table 21 Europe Gout Therapeutics Market, By Disease Condition, 2018 - 2030 (USD Million)
• Table 22 Europe Gout Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 23 Germany Gout Therapeutics Market, By Drug Class, 2018 - 2030 (USD Million)
• Table 24 Germany Gout Therapeutics Market, By Disease Condition, 2018 - 2030 (USD Million)
• Table 25 Germany Gout Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 26 UK Gout Therapeutics Market, By Drug Class, 2018 - 2030 (USD Million)
• Table 27 UK Gout Therapeutics Market, By Disease Condition, 2018 - 2030 (USD Million)
• Table 28 UK Gout Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 29 France Gout Therapeutics Market, By Drug Class, 2018 - 2030 (USD Million)
• Table 30 France Gout Therapeutics Market, By Disease Condition, 2018 - 2030 (USD Million)
• Table 31 France Gout Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 32 Italy Gout Therapeutics Market, By Drug Class, 2018 - 2030 (USD Million)
• Table 33 Italy Gout Therapeutics Market, By Disease Condition, 2018 - 2030 (USD Million)
• Table 34 Italy Gout Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 35 Spain Gout Therapeutics Market, By Drug Class, 2018 - 2030 (USD Million)
• Table 36 Spain Gout Therapeutics Market, By Disease Condition, 2018 - 2030 (USD Million)
• Table 37 Spain Gout Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 38 Denmark Gout Therapeutics Market, By Drug Class, 2018 - 2030 (USD Million)
• Table 39 Denmark Gout Therapeutics Market, By Disease Condition, 2018 - 2030 (USD Million)
• Table 40 Denmark Gout Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 41 Sweden Gout Therapeutics Market, By Drug Class, 2018 - 2030 (USD Million)
• Table 42 Sweden Gout Therapeutics Market, By Disease Condition, 2018 - 2030 (USD Million)
• Table 43 Sweden Gout Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 44 Norway Gout Therapeutics Market, By Drug Class, 2018 - 2030 (USD Million)
• Table 45 Norway Gout Therapeutics Market, By Disease Condition, 2018 - 2030 (USD Million)
• Table 46 Norway Gout Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 47 Asia Pacific Gout Therapeutics Market, By Country, 2018 - 2030 (USD Million)
• Table 48 Asia Pacific Gout Therapeutics Market, By Drug Class, 2018 - 2030 (USD Million)
• Table 49 Asia Pacific Gout Therapeutics Market, By Disease Condition, 2018 - 2030 (USD Million)
• Table 50 Asia Pacific Gout Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 51 Japan Gout Therapeutics Market, By Drug Class, 2018 - 2030 (USD Million)
• Table 52 Japan Gout Therapeutics Market, By Disease Condition, 2018 - 2030 (USD Million)
• Table 53 Japan Gout Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 54 China Gout Therapeutics Market, By Drug Class, 2018 - 2030 (USD Million)
• Table 55 China Gout Therapeutics Market, By Disease Condition, 2018 - 2030 (USD Million)
• Table 56 China Gout Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 57 India Gout Therapeutics Market, By Drug Class, 2018 - 2030 (USD Million)
• Table 58 India Gout Therapeutics Market, By Disease Condition, 2018 - 2030 (USD Million)
• Table 59 India Gout Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 60 South Korea Gout Therapeutics Market, By Drug Class, 2018 - 2030 (USD Million)
• Table 61 South Korea Gout Therapeutics Market, By Disease Condition, 2018 - 2030 (USD Million)
• Table 62 South Korea Gout Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 63 Australia Gout Therapeutics Market, By Drug Class, 2018 - 2030 (USD Million)
• Table 64 Australia Gout Therapeutics Market, By Disease Condition, 2018 - 2030 (USD Million)
• Table 65 Australia Gout Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 66 Thailand Gout Therapeutics Market, By Drug Class, 2018 - 2030 (USD Million)
• Table 67 Thailand Gout Therapeutics Market, By Disease Condition, 2018 - 2030 (USD Million)
• Table 68 Thailand Gout Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 69 Latin America Gout Therapeutics Market, By Country, 2018 - 2030 (USD Million)
• Table 70 Latin America Gout Therapeutics Market, By Drug Class, 2018 - 2030 (USD Million)
• Table 71 Latin America Gout Therapeutics Market, By Disease Condition, 2018 - 2030 (USD Million)
• Table 72 Latin America Gout Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 73 Brazil Gout Therapeutics Market, By Drug Class, 2018 - 2030 (USD Million)
• Table 74 Brazil Gout Therapeutics Market, By Disease Condition, 2018 - 2030 (USD Million)
• Table 75 Brazil Gout Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 76 Mexico Gout Therapeutics Market, By Drug Class, 2018 - 2030 (USD Million)
• Table 77 Mexico Gout Therapeutics Market, By Disease Condition, 2018 - 2030 (USD Million)
• Table 78 Mexico Gout Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 79 Argentina Gout Therapeutics Market, By Drug Class, 2018 - 2030 (USD Million)
• Table 80 Argentina Gout Therapeutics Market, By Disease Condition, 2018 - 2030 (USD Million)
• Table 81 Argentina Gout Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 82 Middle East & Africa Gout Therapeutics Market, By Country, 2018 - 2030 (USD Million)
• Table 83 Middle East & Africa Gout Therapeutics Market, By Drug Class, 2018 - 2030 (USD Million)
• Table 84 Middle East & Africa Gout Therapeutics Market, By Disease Condition, 2018 - 2030 (USD Million)
• Table 85 Middle East & Africa Gout Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 86 Saudi Arabia Gout Therapeutics Market, By Drug Class, 2018 - 2030 (USD Million)
• Table 87 Saudi Arabia Gout Therapeutics Market, By Disease Condition, 2018 - 2030 (USD Million)
• Table 88 Saudi Arabia Gout Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 89 South Africa Gout Therapeutics Market, By Drug Class, 2018 - 2030 (USD Million)
• Table 90 South Africa Gout Therapeutics Market, By Disease Condition, 2018 - 2030 (USD Million)
• Table 91 South Africa Gout Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 92 UAE Gout Therapeutics Market, By Drug Class, 2018 - 2030 (USD Million)
• Table 93 UAE Gout Therapeutics Market, By Disease Condition, 2018 - 2030 (USD Million)
• Table 94 UAE Gout Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 95 Kuwait Gout Therapeutics Market, By Drug Class, 2018 - 2030 (USD Million)
• Table 96 Kuwait Gout Therapeutics Market, By Disease Condition, 2018 - 2030 (USD Million)
• Table 97 Kuwait Gout Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)

List of Figures

• Fig. 1 Market research process
• Fig. 2 Information procurement
• Fig. 3 Primary research pattern
• Fig. 4 Market research approaches
• Fig. 5 Value chain-based sizing & Forecasting
• Fig. 6 QFD modeling for market share assessment
• Fig. 7 Market summary
• Fig. 8 Market trends & outlook
• Fig. 9 Market segmentation & scope
• Fig. 10 Market driver relevance analysis (Current & future impact)
• Fig. 11 Market restraint relevance analysis (Current & future impact)
• Fig. 12 Penetration & growth prospect mapping
• Fig. 13 Gout therapeutics market - PESTLE analysis
• Fig. 14 Porter's Five Forces Analysis
• Fig. 15 Gout therapeutics market outlook key takeaways
• Fig. 16 Gout therapeutics market: Drug class movement analysis
• Fig. 17 Global gout therapeutics market, by drug class, 2018 - 2030 (USD Million)
• Fig. 18 Global gout therapeutics market, 2018 - 2030 (USD Million)
• Fig. 19 Global NSAIDs market, 2018 - 2030 (USD Million)
• Fig. 20 Global corticosteroids market, 2018 - 2030 (USD Million)
• Fig. 21 Global colchicine market, 2018 - 2030 (USD Million)
• Fig. 22 Global urate-lowering agents market, 2018 - 2030 (USD Million)
• Fig. 23 Global gout therapeutics market: Disease condition movement analysis
• Fig. 24 Global gout therapeutics market, by disease condition, 2018 - 2030 (USD Million)
• Fig. 25 Global acute gout market, 2018 - 2030 (USD Million)
• Fig. 26 Global chronic gout market, 2018 - 2030 (USD Million)
• Fig. 27 Global gout therapeutics market: Distribution Channel movement analysis
• Fig. 28 Global gout therapeutics market, by distribution channel, 2018 - 2030 (USD Million)
• Fig. 29 Global retail pharmacy market, 2018 - 2030 (USD Million)
• Fig. 30 Global hospital pharmacy market, 2018 - 2030 (USD Million)
• Fig. 31 Global online pharmacy market, 2018 - 2030 (USD Million)
• Fig. 32 Regional market: Key takeaways
• Fig. 33 Gout therapeutics market regional outlook, 2018 & 2030
• Fig. 34 North America gout therapeutics market, 2018 - 2030 (USD Million)
• Fig. 35 U.S. gout therapeutics market, 2018 - 2030 (USD Million)
• Fig. 36 Canada gout therapeutics market, 2018 - 2030 (USD Million)
• Fig. 37 Europe gout therapeutics market, 2018 - 2030 (USD Million)
• Fig. 38 Germany gout therapeutics market, 2018 - 2030 (USD Million)
• Fig. 39 UK gout therapeutics market, 2018 - 2030 (USD Million)
• Fig. 40 France gout therapeutics market, 2018 - 2030 (USD Million)
• Fig. 41 Italy gout therapeutics market, 2018 - 2030 (USD Million)
• Fig. 42 Spain gout therapeutics market, 2018 - 2030 (USD Million)
• Fig. 43 Denmark gout therapeutics market, 2018 - 2030 (USD Million)
• Fig. 44 Sweden gout therapeutics market, 2018 - 2030 (USD Million)
• Fig. 45 Norway gout therapeutics market, 2018 - 2030 (USD Million
• Fig. 46 Asia Pacific gout therapeutics market, 2018 - 2030 (USD Million)
• Fig. 47 Japan gout therapeutics market, 2018 - 2030 (USD Million)
• Fig. 48 China gout therapeutics market, 2018 - 2030 (USD Million)
• Fig. 49 India gout therapeutics market, 2018 - 2030 (USD Million)
• Fig. 50 South Korea gout therapeutics market, 2018 - 2030 (USD Million)
• Fig. 51 Australia gout therapeutics market, 2018 - 2030 (USD Million
• Fig. 52 Thailand gout therapeutics market, 2018 - 2030 (USD Million
• Fig. 53 Latin America gout therapeutics market, 2018 - 2030 (USD Million)
• Fig. 54 Brazil gout therapeutics market, 2018 - 2030 (USD Million)
• Fig. 55 Mexico gout therapeutics market, 2018 - 2030 (USD Million)
• Fig. 56 Argentina gout therapeutics market, 2018 - 2030 (USD Million)
• Fig. 57 Middle East Africa gout therapeutics market, 2018 - 2030 (USD Million)
• Fig. 58 South Africa gout therapeutics market, 2018 - 2030 (USD Million)
• Fig. 59 Saudi Arabia gout therapeutics market, 2018 - 2030 (USD Million)
• Fig. 60 UAE gout therapeutics market, 2018 - 2030 (USD Million)
• Fig. 61 Kuwait gout therapeutics market, 2018 - 2030 (USD Million
• Fig. 62 Strategy frameworks